Using Charcot–Marie–Tooth disease as a test case, our data would indicate that ATase inhibition may not be effective in patients with PMP22 duplication (classified as CMT1A) but may be effective in patients with PMP22 mutations (classified as CMT1E). Here, PPAT is linked to Charcot-Marie-Tooth disease type 1E.